Related Experiment Video
Updated: Jul 14, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
Admission Hypocalcemia and the Need for Endoscopic and Clinical Interventions among Patients with Upper
Alex Korytny1,2, Fares Mazzawi3, Erez Marcusohn4
1Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel.
Insights
Hypocalcemia (low calcium) is common in patients with nonvariceal upper gastrointestinal bleeding (NV-UGIB) and predicts a need for more interventions. Measuring calcium levels on admission can help identify high-risk patients.
Area of Science:
- Internal Medicine
- Gastroenterology
- Critical Care Medicine
Background:
- Calcium is vital for blood clotting.
- Hypocalcemia is linked to poor outcomes in bleeding patients.
- The role of admission ionized calcium in nonvariceal upper gastrointestinal bleeding (NV-UGIB) requires further investigation.
Purpose of the Study:
- To determine if admission ionized calcium (Ca++) levels predict the need for therapeutic interventions in patients with acute NV-UGIB.
- To assess the association between hypocalcemia and adverse clinical outcomes in NV-UGIB patients.
Main Methods:
- Retrospective cohort study of adult NV-UGIB patients (January 2009 - April 2020).
- Primary outcome: need for clinical intervention (e.g., transfusions, endoscopic, surgical, or angiographic procedures).
- Logistic regression and propensity score matching were used to analyze the association between Ca++ and interventions.
Main Results:
- 34.1% of patients had hypocalcemia (Ca++ <1.15 mmol/L).
- Hypocalcemic patients were significantly more likely to require therapeutic interventions (48.0% vs. 18.5%), endoscopic procedures, and multiple packed cell transfusions.
- Admission ionized calcium was an independent predictor of therapeutic intervention, and its inclusion improved the Modified Glasgow Blatchford score's predictive accuracy.
Conclusions:
- Hypocalcemia is prevalent in NV-UGIB and associated with a more severe clinical course.
- Admission ionized calcium measurement can aid in risk stratification for NV-UGIB patients.
- Further clinical trials are warranted to evaluate the impact of correcting hypocalcemia on patient outcomes.
Introduction:
Calcium is an essential co-factor in the coagulation cascade, and hypocalcemia is associated with adverse outcomes in bleeding patients, including trauma patients, women with postpartum hemorrhage, and patients with intracranial hemorrhage. In this retrospective, single-center, cohort study, we aimed to determine whether admission-ionized calcium (Ca++) is associated with higher rates of therapeutic interventions among patients presenting with acute nonvariceal upper gastrointestinal bleeding (NV-UGIB).
Methods:
Adult patients admitted due to NV-UGIB between January 2009 and April 2020 were identified. The primary outcome was defined as a need for clinical intervention (two or more packed cell transfusions, need for endoscopic, surgical, or angiographic intervention). Univariate and multivariable logistic regression analyses were performed to determine whether Ca++ was an independent predictor of the need for therapeutic interventions. Propensity score matching was performed to adjust the imbalances of covariates between the groups.
Results:
A total of 434 patients were included, of whom 148 (34.1%) had hypocalcemia (Ca++ <1.15 mmol/L). Patients with hypocalcemia were more likely to require therapeutic interventions than those without hypocalcemia (48.0% vs. 18.5%, p < 0.001). Specifically, patients with hypocalcemia were more likely to require endoscopic intervention for control of bleeding (25.0% vs. 15.7%, p = 0.03) and multiple packed cell transfusions (6.8% vs. 0.3%, p < 0.001). Additionally, they had significantly longer hospital stay (5.0 days [IQR 3.0-8.0] vs. 4.0 days [IQR 3.0-6.0], p = 0.01). After adjusting for multiple covariates, Ca++ was an independent predictor of the need for therapeutic intervention (aOR 1.62, 95% confidence interval [CI] 1.22-2.14, p < 0.001). The addition of Ca++ to the Modified Glasgow Blatchford score improved its accuracy in the prediction of therapeutic intervention from AUC of 0.68 (95% CI 0.63-0.72) to 0.72 (95% CI 0.67-0.76), p = 0.02. After incorporation of the propensity score, the results did not change significantly.
Conclusion:
These findings suggest that hypocalcemia is common and is associated with an adverse clinical course in patients with NV-UGIB. Measurement of Ca++ on admission may facilitate risk stratification in these patients. Trials are needed to assess whether the correction of hypocalcemia will lead to improved outcomes.
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Endoscopic Procedures I: Esophagogastroduodenoscopy
During an EGD, the endoscope can be used to:
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations:

